drugset / Trial / NCT06274801
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NaSingle-groupOpen-labelTreatment
Summary
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Timeline
- Start
- 2024-09-03
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seralutinib | Peptide | 90 mg | Inhaled |